Hepatic steatosis in adults on CFTR modulators is commonly associated with cardiometabolic criteria consistent with metabolic dysfunction-associated steatotic liver disease
Journal of Cystic Fibrosis · 2026
DOI: 10.1016/j.jcf.2026.06.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026. Verfasst von Sofia Manioudaki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Care Unit, Sismanogleio General Hospital, Athens, Greece. Hauptthemen laut MEDLINE: Cystic Fibrosis, Fatty Liver. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND/AIMS: Hepatic steatosis (HS) is common in Cystic fibrosis (CF). CF transmembrane conductance-regulator (CFTR) modulators have been associated with improved nutritional status. The controlled attenuation parameter (CAP) is a non-invasive method for assessing HS. This study aimed to evaluate HS and to investigate whether its presence is associated with features suggestive of metabolic dysfunction-associated steatotic liver disease (MASLD). METHODS: We conducted a prospective study (duration 25±2.5 months) including 45 patients receiving elexacaftor/tezacaftor/ivacaftor (treatment duration 32.7 ± 9.9 months). Clinical and laboratory data, as well as non-invasive markers of liver fibrosis, were recorded at enrolment and at final assessment (FA). RESULTS: From enrolment to FA, body mass index (BMI) increased significantly (p < 0.001), whereas HS either persisted or developed during follow-up. At FA, BMI and waist circumference were associated with HS in univariate analysis; however, in multivariate analysis, only BMI remained independently associated with HS [OR 1.338 (95%CI 1.064-1.682), p = 0.013]. Among 12 (26.6%) patients with CAP≥248 dB/m at FA, all but one fulfilled at least one cardiometabolic criterion for MASLD. Overall, liver stiffness measurement and AST-to-Platelet-Ratio Index decreased at FA compared with enrolment (p = 0.044 and p = 0.027, respectively). This improvement persisted after BMI stratification only in patients with BMI
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Intensive Care Unit, Sismanogleio General Hospital, Athens, Greece.
- Department of Gastroenterology, Alexandra General Hospital, Athens, Greece.
- 3rd Department of Internal Medicine and Liver Outpatient Clinic, Evangelismos General Hospital, Athens, Greece.
- 2nd Department of Internal Medicine and Research Laboratory, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.
- Adult Cystic Fibrosis (CF) Unit, Sismanoglio Hospital, Athens, Greece.
- 2nd Department of Internal Medicine and Research Laboratory, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece. Electronic address: alexopou@ath.forthnet.gr.
Zitieren
APA
Manioudaki, S., Vasilieva, L., Geladari, E., Mani, I., Sevastianos, V., Diamantea, F., & Alexopoulou, A. (2026). Hepatic steatosis in adults on CFTR modulators is commonly associated with cardiometabolic criteria consistent with metabolic dysfunction-associated steatotic liver disease. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2026.06.008
Vancouver
Manioudaki S, Vasilieva L, Geladari E, Mani I, Sevastianos V, Diamantea F, et al. Hepatic steatosis in adults on CFTR modulators is commonly associated with cardiometabolic criteria consistent with metabolic dysfunction-associated steatotic liver disease. Journal of Cystic Fibrosis. 2026. doi:10.1016/j.jcf.2026.06.008
BibTeX
@article{Manioudaki2026,
author = {Manioudaki, Sofia and Vasilieva, Larisa and Geladari, Eleni and Mani, Iliana and Sevastianos, Vasilios and Diamantea, Filia and Alexopoulou, Alexandra},
title = {Hepatic steatosis in adults on CFTR modulators is commonly associated with cardiometabolic criteria consistent with metabolic dysfunction-associated steatotic liver disease},
journal = {Journal of Cystic Fibrosis},
year = {2026},
doi = {10.1016/j.jcf.2026.06.008}
}
EUVIMED